185 related articles for article (PubMed ID: 34106609)
1. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report.
Yamaguchi K; Tsuchihashi K; Tsuji K; Kito Y; Tanoue K; Ohmura H; Ito M; Isobe T; Ariyama H; Kusaba H; Akashi K; Baba E
Medicine (Baltimore); 2021 May; 100(19):e25773. PubMed ID: 34106609
[TBL] [Abstract][Full Text] [Related]
2. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
4. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
5. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
Suyama T; Fukuda Y; Soda H; Ogawara D; Iwasaki K; Hara T; Yoshida M; Harada T; Umemura A; Yamaguchi H; Mukae H
Thorac Cancer; 2018 Jun; 9(6):750-753. PubMed ID: 29667757
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
8. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
9. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
12. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
14. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
[TBL] [Abstract][Full Text] [Related]
15. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
16. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
Kubota Y; Yoshimura K; Hamada K; Hirasawa Y; Shida M; Taniguchi M; Matsui H; Ariizumi H; Ishiguro T; Suzuki N; Ohkuma R; Sambe T; Ishida H; Horiike A; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Kobayashi S; Tsunoda T
In Vivo; 2021; 35(3):1865-1875. PubMed ID: 33910874
[TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
[TBL] [Abstract][Full Text] [Related]
18. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
19. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]